BioWorld

Oct. 18, 2007

Studies Shine Light, Literally, On Neural Substrates Of Sleep

Cubist Gets Option To Acquire Illumigen; Funds HCV Drug

Cubist Pharmaceuticals Inc. moved to expand its pipeline beyond Cubicin (daptomycin for injection) by picking up an exclusive option to acquire Illumigen Biosciences Inc. (BioWorld Today) Read More

Pharmion's Amrubicin Begins Pivotal Trial In SCLC Patients

Osiris Targets GVHD, Crohn's With Stem Cell Therapy

Other News To Note

Financings Roundup

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for April 23, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for April 21, 2026

Psychedelic space expanding on Trump’s EO

BioWorld

Timothy Leary is dead, but he could be on the outside looking in with a smile on his face as U.S. President Donald Trump’s latest executive order (EO) fuels a...

At AACR: Epigenetic fingerprints in metastases track tumor origin

BioWorld

When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...

Illustration of human face that looks abstract and digital

AACR 2026: The age of agentic AI in oncology

BioWorld Science

New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...